NCT06573424Completed
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
Efficacy AND Multiomic Molecular Characterization of Tirellizumab Combined With Anlotinib in in MSS/pMMR Metastatic Colorectal Cancer: Data From a Retrospective Multicenter Study
Source: ClinicalTrials.gov · Last updated 1 May 2025
Brief summary (registry, in English)
To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 124 (actual)
- First submitted
- 15 Aug 2024
- Start date
- 1 May 2024
- Primary completion date
- 1 Jul 2024
- Lead sponsor
- fan li
- Diseases
- Colorectal cancer
- NCT number
- NCT06573424
What you commit to
- Study type: Observational
- Participants enrolled: 124
- From 1 May 2024 to the primary completion date, 1 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with antirotinib, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibodies or any other antibody or drug that specifically targets T cell co-stimulation or checkpoint pathways
Other illness
- Patients with other malignant tumors
Other
- Follow-up was less than 30 days
Who the study is looking for
- 18-70 years old
- Patients with mss colorectal cancer who have been confirmed by pathology and have relapsed or failed multiline therapy
- Patients who have been treated with anlotinib monotherapy(12 mg qd, d1-14; 21 days per cycle) or anlotinib(12 mg qd, d1-14; 21 days per cycle)+ tislelizumab(200 mg, once every 3 weeks)
- the presence of at least one measurable target lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Daping Hospital, Third Military Medical University Coordinator of this site? Confirm its status | Chongqing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.